Today: 30 June 2026
AST SpaceMobile stock rises today after insider-buy filing as options heat up on BlueBird rollout
30 December 2025
2 mins read

AST SpaceMobile stock rises today after insider-buy filing as options heat up on BlueBird rollout

NEW YORK, December 30, 2025, 17:15 ET — After-hours

  • AST SpaceMobile shares were last up about 4% in after-hours trading Tuesday.
  • A regulatory filing showed a director bought shares last week under a pre-set trading plan.
  • Nasdaq data flagged unusually heavy ASTS options activity, led by $80 strike calls.

AST SpaceMobile, Inc. shares rose on Tuesday and were last up about 4.3% at $74.68 in after-hours trading, extending a volatile stretch for the satellite-to-smartphone company.

The move matters because investors are trying to pin down how quickly AST can turn recent launch milestones into repeatable deployment — and, eventually, commercial service that supports the stock’s premium expectations.

In the near term, traders have been keying off any new disclosures on insider activity, partner readiness and derivatives positioning as proxies for sentiment ahead of the company’s next operational updates.

A Form 4 filing on Monday showed director Keith R. Larson purchased 625 shares at $80 apiece on Dec. 24, holding the shares indirectly through an IRA.

The filing also indicated the trade was made under a Rule 10b5-1 plan — a pre-arranged instruction that can automate buying or selling on a set schedule and is commonly used to limit the appearance of trading on material nonpublic information.

Options activity also ran hot. Nasdaq data showed 81,604 ASTS contracts traded by mid-afternoon, with the heaviest flow in $80 strike calls expiring Jan. 2, 2026.

AT&T, one of AST’s carrier partners, added to the drumbeat in a company blog post on Monday. Robert Walters, an AT&T senior vice president, wrote the BlueBird 6 launch brings AT&T “one step closer to making broadband satellite connectivity available to our customers.” AT&T Newsroom

The same post said AST is “on track to complete four more launches by March 2026,” and that AT&T plans to offer a beta satellite service to a select number of customers and public safety users in the first half of next year, with a commercial launch to follow. AT&T Newsroom

AST last week announced the successful orbital launch of BlueBird 6, its first next-generation satellite designed to deliver 4G and 5G broadband directly to standard, unmodified smartphones — “direct-to-device” service that does not require special hardware on the handset. Business Wire+1

The company said BlueBird 6 carries a communications array of nearly 2,400 square feet, part of a broader push to expand capacity and coverage as it scales a low-Earth-orbit constellation.

Investors are now watching for signs the satellite is commissioning smoothly — the step-by-step process of deploying hardware, establishing links and verifying performance — and for any concrete milestones on when additional satellites will follow.

The next major scheduled datapoint is results. ASTS’s next earnings release is expected around March 2, 2026, according to Zacks’ calendar, though the company has not confirmed a date.

On Tuesday, ASTS traded between $72.07 and $78.27, with more than 17 million shares changing hands, underscoring how quickly positioning can swing as the market prices the pace — and the cost — of the rollout.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop